Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.

ABSTRACT:

Background

Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are found downstream of the type II cytokine receptor family used by a number of T_H17 cell-associated cytokines for signal transduction. These cytokines lead to the secretion of antiviral and antimicrobial peptides (AMPs) by keratinocytes or synoviocytes. Blocking the JAK pathway might result in a diminished secretion of antimicrobial and antiviral peptides causing higher susceptibility to infections in patients treated with JAK inhibitors.

Methods

We treated primary human k

SUBMITTER: Hawerkamp HC 

PROVIDER: S-EPMC8138978 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature